₹225 per dose plus applicable GST. The move comes after a letter was written by Prakash Kumar Singh, Director, Serum Institute of India (SII) to the Union health ministry on March 27, the sources said.
As per an official source, Singh had reportedly stated in his letter to the ministry that Covovax, which has been approved by DCGI, WHO, and USFDA, is a world-class vaccine.
He further advocated for its inclusion on the CoWIN portal as a heterologous booster dose for adults. Covovax can be administered to those who have already been vaccinated with Covishield or Covaxin.
The COVID-19 Working Group, led by Dr. N.K. Arora, had reportedly recommended to the Health Ministry last month that Covovax be included on the CoWIN portal as a heterologous booster dose for adults who have already received two doses of either Covishield or Covaxin.